Reversibility of Diastolic Disfunction in Septic Shock
- Conditions
- Diastolic DysfunctionSeptic Shock
- Registration Number
- NCT03198611
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Brief Summary
Objectives: To study the prognostic value of the evolution of diastolic function according to fluid balance in patients admitted to the ICU with a diagnosis of septic shock, in terms of mortality (ICU and hospital) and mortality at 90 days.
2.4. Secondary objectives: A) Incidence and reversibility of myocardial dysfunction (left ventricular systolic and diastolic) in septic shock.
B) Incidence and reversibility of diastolic dysfunction according to the echocardiographic criterion used.
C) Incidence and reversibility of right ventricular systolic dysfunction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 350
- Patients admitted to the ICU with diagnosis of septic shock, and stay longer than 48h
- No echocardiographic window
- Fatal prognosis with do not resuscitate orders at admission
- Previous history of Ischemic cardiomyopathy
- Valvular prosthesis
- Advanced degree of valvular disorder
- Advanced degree of pericardial effusion
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality at 90 days 90 days Dead at 90 days
- Secondary Outcome Measures
Name Time Method ICU mortality 90 days Dead in ICU
In hospital mortality 90 days Dead in hospital
Change in incidence of diastolic dysfunction From first 24 hours of ICU admission until 48h, 72h and 7 days from admission Change in incidence of diastolic dysfunction according to the different criteria used.
Incidence of myocardial disfunction During the first 24 hours of ICU admission According to the criteria specified at groups section
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (4)
Hospital Verge de la Cinta
🇪🇸Tortosa, Tarragona, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital del Vall d´Hebron
🇪🇸Barcelona, Spain
Hospital Verge de la Cinta🇪🇸Tortosa, Tarragona, SpainFerran Roche-CampoContact